ABO-Incompatible Liver Transplantation Is an Underused Resource for Improving Access to Liver Transplantation
Transplantation Proceedings · 2025
DOI: 10.1016/j.transproceed.2025.10.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2025. Verfasst von Angela L Hill und 12 weiteren Autor:innen. Beteiligte Einrichtung: Section of Abdominal Transplantation, Division of General Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, MO 63110. El…. Hauptthemen laut MEDLINE: Liver Transplantation, ABO Blood-Group System, Blood Group Incompatibility, End Stage Liver Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: United Network for Organ Sharing.
Abstract (Originalsprache)
BACKGROUND: Historically, ABO incompatibility (ABOi) has been considered a relative contraindication to liver transplant (LT) due to inferior postoperative outcomes. We seek to reassess ABOi LTs as an underused graft supply. METHODS: We retrospectively reviewed all adult and pediatric patients who underwent LT, 1987-2022. Recipients were categorized by donor blood type compatibility: incompatible (ABOi), compatible (ABOc), and identical (ABOid). Propensity scoring of 1:1:1 was performed to account for recipient age and acuity at transplant. RESULTS: Of 193,751 LTs, 2699 were ABOi (1.4%). ABOi recipients had the highest proportion of status 1 listings (22.5% versus 20.5% ABOc, 4.9% ABOid, P < 0.0001) and the highest model for end-stage liver disease (30 versus 28 ABOc, 26 ABOid, P < 0.0001) and pediatric end-stage liver disease scores at transplant (33 versus 28 ABOc, 25 ABOid, P < 0.0001). When analyzing the unmatched cohort, ABOi was associated with worse GS (HR 1.2, P < 0.001), OS (HR 1.1, P = 0.033), and increased rates of retransplantation (HR 1.35, P = 0.001). However, after performing propensity matching, there were no differences in GS, OS, or retransplantation between groups. CONCLUSIONS: There is no difference in outcomes between ABOi LT recipients and recipients of ABOc and ABOid grafts after accounting for recipient age and acuity. ABOi LT may decrease blood group disparities and improve timely LT access.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Abdominal Transplantation, Division of General Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, MO 63110. Electronic address: Angela1@wustl.edu.
- Section of Abdominal Transplantation, Division of General Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, MO 63110.
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Washington University in St. Louis, St. Louis, MO 63110.
Förderung
- United Network for Organ Sharing
Zitieren
APA
Hill, A. L., Kiani, A. Z., Vachharajani, N., Martens, G. R., Kulkarni, S., Harsin, C., Alomar, O., Chaparro-Zaraza, D. F., Coker, T., Lindemann, J. D., Chapman, W. C., Doyle, M. B., & Khan, A. S. (2025). ABO-Incompatible Liver Transplantation Is an Underused Resource for Improving Access to Liver Transplantation. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2025.10.004
Vancouver
Hill AL, Kiani AZ, Vachharajani N, Martens GR, Kulkarni S, Harsin C, et al. ABO-Incompatible Liver Transplantation Is an Underused Resource for Improving Access to Liver Transplantation. Transplantation Proceedings. 2025. doi:10.1016/j.transproceed.2025.10.004
BibTeX
@article{Hill2025,
author = {Hill, Angela L and Kiani, Amen Z and Vachharajani, Neeta and Martens, Gregory R and Kulkarni, Sakil and Harsin, Caleb and Alomar, Omar and Chaparro-Zaraza, Diego F and Coker, Tess and Lindemann, Jessica D and Chapman, William C and Doyle, Majella B and Khan, Adeel S},
title = {ABO-Incompatible Liver Transplantation Is an Underused Resource for Improving Access to Liver Transplantation},
journal = {Transplantation Proceedings},
year = {2025},
doi = {10.1016/j.transproceed.2025.10.004}
}
EUVIMED